EXSCIENTIA
Exscientia , an AI-driven pharmatech company with a mission to revolutionise how drugs are discovered, and GT Apeiron Therapeutics （Apeiron） , a Shanghai based company focused on novel oncology drugs, announced today a strategic research and development collaboration agreement. The collaboration will leverage the patient-centric AI-first capabilities of Exscientia to accelerate the discovery of multiple small molecule therapeutic drug candidates designed to selectively treat aberrant cell cycle driven cancers and build a pipeline of CDK novel therapies. All pipeline products will be equally owned and Exscientia holds an equity stake in Apeiron.
This expanded collaboration follows the successful design of multiple selective CDK7 compounds. The potent, highly selective, non-covalent CDK7 compounds have demonstrated consistent tumour responses in xenograft models as well as exceptional pharmacokinetics. In addition, using live primary tissue samples from ovarian cancer patients, the CDK7 inhibitors showed both enhanced tumour cell cytotoxicity as well as selectivity over immune cells in the same microenvironment.
“Based on what they have already achieved , Exscientia is clearly the leader in AI-driven drug discovery, and we have witnessed this first-hand in our collaboration so far,” stated Dr. Mingxi Li, President of GT Apeiron Therapeutics. “We have been incredibly impressed by the combined power of the AI design and use of patient data to optimize and select molecules that are more likely to give positive effects in the clinic. This joint venture is a significant step in building GT Apeiron’s valuable and robust pipeline of CDK inhibitor drugs and substantially accelerates our early-stage output and progression towards being a clinical stage biotech company.”
“We are driven to bring drugs to market that make a difference for patients,” says Andrew Hopkins, chief executive officer of Exscientia. “Apeiron bring a focus and an expertise on the biological basis of multiple cancers and helps us to create better drugs for better outcomes in the clinic and beyond. This collaboration has already proven to be capable of delivering potential drug candidates with promising patient-relevant data, and we look forward to extending that into a portfolio of multiple clinical assets.”
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created. Exscientia’s AI platform has now designed three drugs that are in Phase 1 human clinical trials.
Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.
Exscientia has offices in Oxford, Miami, Osaka and Dundee. For more information visit us on www.exscientia.ai Social media: Twitter @exscientiaAI . LinkedIn https://www.linkedin.com/company/ex-scientia/
About GT Apeiron Therapeutics
GT Apeiron Therapeutics is strategically based in Shanghai and in the San Francisco Bay Area, with significant collaborations in the UK enabling us to tap into technologies and talent from all three continents. Our team and partners bring together deep expertise in oncology and drug discovery to enable efficient and scalable discovery and development of novel drugs. To learn more, visit http://www.apeiron-bio.com/ Social media: LinkedIn https://www.linkedin.com/company/gt-apeiron-therapeutics/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005394/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cessna Citation CJ3 Gen2 achieves FAA type certification, bringing the most comprehensive Gen2 enhancements to market14.10.2025 00:00:00 CEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, announced the Cessna Citation CJ3 Gen2 has achieved Federal Aviation Administration (FAA) type certification, bringing the most comprehensive Citation Gen2 investment to market. Based on customer feedback, enhancements throughout the aircraft include Garmin autothrottle technology, an additional 4.5 inches of legroom for pilots and a fully customizable cabin environment. After completing 445 flight test hours, the light jet is expected to enter into service this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013311527/en/ Cessna Citation CJ3 Gen2 achieves FAA type certification, bringing the most comprehensive Gen2 enhancements to market (Photo Credit: Textron Aviation). “FAA certification of the CJ3 Gen2 is an example of Textron Aviation’s leadership in certifying aircraft,” said Chris Hearne, senior vice president, Engineering & Programs. “This aircraft de
Cessna Citation M2 Gen2 with Garmin Autothrottles Achieves FAA Certification, Bringing Greater Control and Precision to Pilots14.10.2025 00:00:00 CEST | Press release
The Cessna Citation M2 Gen2 with Garmin Autothrottles recently received certification from the Federal Aviation Administration (FAA), bringing greater control and precision to pilots. The integration of Garmin’s Autothrottle system in the M2 Gen2 further supports the most delivered light-entry jet’s capabilities by optimizing engine power, simplifying flight management and increasing overall operating efficiency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013861341/en/ Cessna Citation M2 Gen2 with Garmin Autothrottles achieves FAA certification, bringing greater control and precision to pilots (Photo Credit: Textron Aviation). The Cessna Citation M2 Gen2 is designed and produced by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. The flight test program for the Citation M2 Gen2 with autothrottles completed nearly 300 flight test hours and numerous certification tests, adhering to stringent certification stan
HCLTech Delivers Robust Performance in Q2FY26 with Revenue Growth of 4.6%13.10.2025 20:08:00 CEST | Press release
Deal wins at $2.6B; Advanced AI revenue crosses $100m HCLTech, a leading global technology company, reported 4.6% YOY revenue growth in constant currency (CC) for the quarter ended September 30, 2025. USD revenue was at $3.6 billion, up 5.8% YoY. The company revised its Services Revenue growth (CC) guidance to 4%-5%, while retaining the overall revenue and margin guidance for FY26. “We had a standout quarter on every front — marked by strong execution, growing demand for our AI-powered solutions and Advanced AI revenue exceeding $100 million this quarter. Our AI strategy is no longer just a vision; it is now a measurable driver of growth, differentiation and innovation. We are transitioning into an AI monetization phase. For the first time, our new bookings surpassed $2.5 billion, without reliance on any mega deal,” said C Vijayakumar, CEO & Managing Director, HCLTech. HCLTech’s Services revenue grew by 5.5% YoY (CC). Digital revenue was up 15% YoY (CC) and now accounts for 42% of Serv
Cessna Citation Ascend Makes World Debut at NBAA-BACE in Las Vegas13.10.2025 19:00:00 CEST | Press release
The Cessna Citation Ascend landed today at Henderson Executive Airport in Las Vegas, marking its world debut at the 2025 National Business Aviation Association Business Aviation Convention & Exhibition (NBAA-BACE). The aircraft, which flew to the show using sustainable aviation fuel, will be on display Tuesday, October 14 and Wednesday, 15 alongside other industry-leading Cessna Citation business jets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013102318/en/ Cessna Citation Ascend makes world debut at NBAA-BACE in Las Vegas (Photo Credit: Textron Aviation) The Cessna Citation Ascend is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. “We asked our customers what they wanted in this iconic aircraft, and our teams worked to bring their vision for the Citation Ascend to life,” said Lannie O’Bannion, senior vice president, Sales & Marketing. “With the aircraft making its debut at NBAA
Power Integrations Details 1250 V and 1700 V PowiGaN Technology for Next-Generation 800 VDC AI Data Centers13.10.2025 17:05:00 CEST | Press release
Company is collaborating with NVIDIA on 800 VDC power architecture; new white paper shows advantages of 1250 V PowiGaN technology vs. 650 V GaN and 1200 V SiC Power Integrations (NASDAQ: POWI), the leader in high-voltage integrated circuits for energy-efficient power conversion, today outlined the benefits of its PowiGaN™ gallium-nitride technology for next-generation AI data centers. The capabilities of 1250 V and 1700 V PowiGaN technology for 800 VDC power architectures are explained in a new white paper from Power Integrations, published at the 2025 OCP Global Summit in San Jose, where NVIDIA provided an update on the 800 VDC architecture. Power Integrations is collaborating with NVIDIA to accelerate the transition to 800 VDC power and megawatt-scale racks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013503136/en/ Power Integrations details 1250 V and 1700 V PowiGaN technology for next-generation 800 VDC AI data cen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom